Search

There is currently no optimal scaffold for the transplantation of limbal stem cells (LSCs) to induce corneal reconstruction after corneal alkali burns. This study attempts to fabricate a novel in situ Alginate‐Chitosan hydrogel (ACH) for LSCs transplantation. Sodium alginate dialdehyde (SAD), a biological crosslinker, was prepared by periodate‐mediated sodium alginate oxidization. Carboxymethyl chitosan was rapidly crosslinked with SAD via Schiff's base formation between the available aldehyde and amino groups. The ACH is rapidly formed on the wound surface by self‐crosslinking without adding any chemical crosslinking component. Gelation time, transmittance, microscopic structure, equilibrium swelling, cytotoxicity, histocompatibility and degradability of the hydrogel were all examined. Rabbit primary LSCs were encapsulated in the hydrogel and transplanted to alkali burn wounds in vivo. Cornea reconstruction was evaluated by visual observation, slit lamp, histological analysis, and immunofluorescence staining. Results showed that the in situ hydrogel was highly transparent, gelated quickly, biocompatible, and had low cytotoxicity. LSCs cultured in vitro expressed the stem marker p63 but lacked the differentiated epithelial markers cytokeratin 3 and 12. Furthermore, the hydrogel encapsulating LSCs could be formed quickly on the alkali burn wound of the cornea and was shown to significantly improve epithelial reconstruction. Taken together, treatment with this novel in situ hydrogel‐mediated LSC transplantation system may serve as a rapid and effective method for corneal wound healing. © 2018 The Authors. Journal of Biomedical Materials Research Part A published by Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 742–754, 2019.

Objectives We aimed to investigate the impact of angiotensin-converting enzyme inhibitors (ACEIs) on hematocrit values in those with heart failure, and the relationship between incident anemia and mortality. Background Prevalent anemia is an independent risk factor for morbidity and mortality in those with heart failure. Studies in patients with polycythemia have demonstrated that ACEIs are effective in lowering hematocrit values. Methods We used the Studies Of Left Ventricular Dysfunction (SOLVD) database to compare the odds of developing new anemia at one year in patients who were not anemic at entry and who were randomized to enalapril or placebo. Cox proportional hazards models were utilized to determine the impact of incident and prevalent anemia on subsequent mortality. Results Enalapril increased the odds of incident anemia (hematocrit ≤39% in men or ≤36% in women) at one year by 48% (odds ratio [OR] 1.48, 95% confidence interval [CI] 1.20 to 1.82) in unadjusted and 56% (OR 1.56, 95% CI 1.26 to 1.93) in adjusted models. With multivariate analysis, prevalent anemia at randomization was associated with a 44% (hazard ratio [HR] 1.44, 95% CI 1.31 to 1.66) increase in all-cause mortality, whereas incident anemia after randomization was associated with a 108% increase (HR 2.08, 95% CI 1.82 to 2.38). After adjusting for incident and prevalent anemia, use of enalapril was associated with a survival benefit. Conclusions Enalapril was associated with increased odds of developing anemia at one year. Those with periods of time with incident anemia had the poorest survival, followed by those with prevalent anemia, then those without anemia. Enalapril was protective of overall mortality after adjusting for incident anemia and in those with prevalent anemia.